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AbstrAct
Niemann-Pick type C is an uncommon 
neurodegenerative lysosomal storage disorder 
that can cause a progressive neuropsychiatric 
syndrome associated with supranuclear vertical 
gaze palsy and a movement disorder. There have 
been recent developments in testing that make 
diagnosis easier and new therapies that aim to 
stabilise the disease process. A new biochemical 
test to measure serum cholesterol metabolites 
supersedes the skin biopsy and is practical and 
robust. It is treatable with miglustat, a drug 
that inhibits glycosphingolipid synthesis. We 
describe a patient, aged 22 years, with juvenile-
onset Niemann-Pick type C who presented 
with seizures and a label of ‘cerebral palsy’. 
We describe the approach to this syndrome in 
general, and highlight the classical features and 
red flags that should alert a neurologist to this 
treatable condition.
cAse presentAtion
A 29-year-old woman was referred to us 
with a progressive syndrome. There was 
no neurological disease in her family; 
however, there had been no contact with 
her biological father since his mid-thir-
ties. She had been born at term with no 
perinatal insult, hypoglycaemia or jaun-
dice. Her early developmental milestones 
had been normal and she had attended 
a mainstream primary school. She rode 
horses and competed in dressage events.
Her problems started at secondary 
school during which she acquired the 
label of ‘cerebral palsy’. She fell behind 
her peers and needed extra educational 
support in class. She developed prob-
lems with concentration and mobility. 
Her mother noted that she moved her 
head down when she had to look down, 
and that she needed to raise objects to 
eye level to examine them. She became 
unsteady on her feet but could still walk 
unaided. At aged 15 years, she moved 
from secondary school to a facility to 
provide life skills training for adolescents 
with special needs. She could read and 
write at this stage and began to work as a 
shop assistant.
Over the next few years, she developed 
posturing of her right foot and fidgeting 
movements of her mouth, face, arms and 
legs. She had no difficulties with stiffness, 
sensory problems, bladder or bowel issues. 
Her balance worsened and she began 
to fall. Her speech was stuttering but 
she remained independent. She became 
increasingly unsteady and depended more 
on her mother for support. She acquired 
a wheelchair. Her speech regressed from 
being able to talk in sentences to only 
being able to say a few words.
At the age of 22 years, she presented 
to her local neurology department 
with nocturnal generalised tonic-clonic 
seizures. She had clusters of seizures 
for every few months and was initially 
treated with sodium valproate; this was 
subsequently withdrawn following deteri-
orating cognition and balance, and leveti-
racetam started. She became seizure-free 
after 2 years on 1000 mg daily. Episodes 
of head drop also started at the same 
time as the seizures. These occurred after 
laughter and recovered in seconds. The 
episodes of head drop decreased at the 
same time as the seizures were managed. 
She had no excessive daytime sleepi-
ness, night terrors, dream recall or sleep 
paralysis. At age 28, she developed swal-
lowing difficulties and started a soft diet. 
Her mood was stable and there were no 
obvious symptoms to suggest depression 
or psychosis.
On examination when aged 29, she was 
alert and responsive. She had an asym-
metrical grimace of her face and invol-
untary movements of her face, arms and 
legs (figure 1, for examination see online 
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Figure 1 (A) Dystonic posturing of the patient’s right arm and 
leg. (B) Patient attempting downward gaze followed by (C) this 
being overcome during fixation while her head is tilted back, 
demonstrating her supranuclear gaze palsy.
Figure 2 (A) MR scan of brain (T2-weighted sagittal) in 2012 
(image quality degraded by movement artefact) and (B) a 
corresponding section from 2018 showing prominent cerebellar 
and corpus callosal atrophy.
supplementary video). Her speech was slow. She took 
a few steps with the help of two people but was very 
unsteady and had dystonic posturing of her arms and 
legs. She had a vertical supranuclear gaze palsy and 
a full range of voluntary horizontal eye movement. 
Horizontal saccades to target and command were 
slow. There was no spasticity and her reflexes were 
normal with downgoing plantar responses. Sensation 
was normal. Her Addenbrookes Cognitive Examina-
tion gave a total score of 24/100 with impairments in 
all domains: attention and orientation 6/18; memory 
2/26, fluency 2/14; language 10/26; visuospatial 4/16. 
She had a normal systemic medical examination and 
had no organomegaly. Slit lamp examination in the eye 
department was normal.
She had a mild iron deficiency anaemia. Her normal 
or negative blood investigations included renal, liver 
and thyroid profile, C-reactive protein, erythrocyte 
sedimentation rate, anti-nuclear and related anti-
bodies, immunoglobulins, serum protein electropho-
resis, HIV, syphilis and a blood film for acanthocytes. 
Serum caeruloplasmin, amino acids and very-long-
chain fatty acids were normal. Urinary acylcarnitine 
profile and organic acids were normal.
MR scan of brain showed progressive cerebellar 
and corpus callosum atrophy over 7 years (figure 2). 
Cerebrospinal fluid (CSF) studies showed normal 
cells, protein and glucose (plasma 5.2 mmol/L, CSF 
3.6 mmol/L) and negative DNA PCR for Tropheryma 
whipplei. ECG was normal. EEG at 29 years showed 
slow transients with spike components in the temporal 
regions but no seizure activity.
DiFFerentiAl DiAgnoses
This patient presented with a progressive neurological 
syndrome that developed over ten years from adoles-
cence, comprising seizures, cognitive deterioration, 
cataplexy, supranuclear vertical gaze palsy, swallowing 
difficulties, ataxia and dystonia. This implicates the 
cerebrum, basal ganglia, cerebellum and brainstem in 
the disease pathophysiology. Progressive genetic and 
metabolic conditions were considered most likely.
The individual components of the disorder have 
a broad differential diagnosis but this combination 
strongly suggested Niemann-Pick type C. The differ-
ential diagnosis of a progressive ataxia with an extra-
pyramidal syndrome also includes spinocerebellar 
ataxia type-2, 3, 17, ataxia telangiectasia and neuro-
acanthocytosis.1 We considered Huntington’s disease 
and dentato-rubro-pallido-luysian atrophy due to the 
cognitive, cerebellar and extrapyramidal features, but 
the supranuclear gaze palsy is atypical. Her dystonia 
and seizures could point to glucose transporter type 
1 deficiency; typically, this would be absence seizures 
starting before the age of 4 years and the normal CSF 
glucose would go against this. Wilson’s disease can 
have a variable presentation with ataxia, dystonia and 
gaze palsy and is of course treatable. There were no 
Kayser-Fleischer rings but serum caeruloplasmin was 
also tested. Whipple’s disease can cause an ophthal-
moplegia and movement disorder, but there were no 
gastrointestinal features and CSF PCR was negative. 
Lysosomal storage disease such as Gaucher’s disease 
type A can cause all the symptoms our patient described 
but these patients usually present with an early hori-
zontal supranuclear palsy. The serum oxysterol test for 
Niemann-Pick type C fell into the 95% limits for the 
disorder at 61.5 ng/mL (normal range 9.6 to 37, 95% 
CI for disorder 39.3 to 811.9).
Discussion
niemann-pick type c
Niemann-Pick type C is a pan-ethnic neurodegenera-
tive disorder caused by the accumulation of glycosphin-
golipids. Mutations in either the NPC1 or NPC2 gene 
are associated with abnormal endosomal–lysosomal 
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Key points
 ► Cerebral palsy produces a fixed deficit—progressive 
‘cerebral palsy’ needs re-evaluation.
 ► Niemann-Pick type C is a rare cause of a vertical 
supranuclear gaze palsy and of progressive movement 
disorder.
 ► Many patients with this condition have cataplexy.
 ► Testing for serum oxysterol can give a rapid diagnosis. 
Miglustat can stabilise the disease and sometimes 
improve cognitive function and swallowing.
trafficking resulting in the accumulation of lipids in 
the lysosomes. It has a predicted prevalence as high as 
1:19 000–36 000 based on exome sequencing data of 
known disease-causing mutations.2 Its ‘classical’ inci-
dence is approximately 1:100 000.3
The clinical spectrum of Niemann-Pick type C ranges 
from a rapidly progressive neonatal form to a slowly 
progressive adult-onset neurodegenerative syndrome, 
and patients can live into the seventh decade of life.4 
The early onset form usually also presents with choles-
tatic jaundice, hepatosplenomegaly and/or acute liver 
failure; these features may all be absent from the late-
onset form.
Gelastic cataplexy is more common in early onset 
forms. However, a consistent feature is a vertical 
supranuclear gaze palsy, with downward gaze affected 
initially before vertical gaze. MR imaging of the brain 
may not help but characteristic findings include cere-
bellar and corpus callosal atrophy.
the role of oxysterols in diagnosis
Historically, the diagnosis of Niemann-Pick type C 
was cumbersome and made using cholesterol ester-
ification studies and filipin staining of cultured skin 
fibroblasts.5 Recently, genetic testing of the NPC1 
and NPC2 genes is the most widely performed and 
accessible test. However, in 10% of patients, only 
one pathogenic mutation can be identified, and new 
mutations of uncertain significance may be identified 
in some patients.
Mutations of either gene also affect cellular traf-
ficking of cholesterol, and detecting oxidative choles-
terol metabolites can be diagnostic for Niemann-Pick 
type C. Serum oxysterol can be used as a first-line test 
with subsequent genetic confirmation and has a posi-
tive predictive value of >97%.6 It may be elevated in 
other metabolic disorders such as acid sphingomyeli-
nase deficiency and lysosomal acid lipase deficiency, 
and to a lesser degree cerebrotendinous xanthomatosis. 
However, an elevated oxysterol along with classical 
clinical findings support a diagnosis of Niemann-Pick 
type C.
Miglustat as a treatment for niemann-pick type c
Although there is no cure for this condition, cohort 
studies and randomised controlled trials have iden-
tified miglustat, a substrate reduction therapy, as a 
treatment option.7 8 In some patients, the drug halts or 
attenuates disease progression, and it is the first drug 
that shows both animal and clinical data supporting 
a disease-modifying benefit for Niemann-Pick type C. 
Consensus guidelines indicate that the drug should 
be offered to all patients unless they have a profound 
dementia resulting in the need for 24 hours care, 
inability to walk without a wheelchair, complete lack 
of verbal communication or swallowing difficulties 
profound enough to require feeding through a percuta-
neous endoscopic gastrostomy.9 Miglustat was initially 
authorised for use in exceptional circumstances by 
the European Medicines Agency in 2002 and then 
following trial data with a broader use from 2009.
conclusion
Niemann-Pick type C is a rare lysosomal storage 
disorder of which all neurologists should be aware, as 
it is treatable. A progressive vertical supranuclear gaze 
palsy, gelastic cataplexy, ataxia, dystonia and dementia 
strongly suggest the diagnosis. Serum biomarkers such as 
oxysterol have become available since previous reports 
based on the Filipin test,10 which is labour intensive, 
making diagnosis easier. Currently, there are drug treat-
ment options available and more are being tested in clin-
ical trials that may benefit more patients in the future. 
An association, Niemann-Pick UK ( www. npuk. org), 
exists to support patients and families experiencing the 
condition in the UK.
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